Whole genome sequencing of M. tuberculosis for disease control in high-burden settings: study protocol for a cluster randomized controlled trial evaluating different community-wide intervention strategies in rural Madagascar.
Cluster randomized controlled trial
Disease outbreak
Molecular epidemiology
Tuberculosis
Whole genome sequencing
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
15
05
2024
accepted:
07
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Retrospective and descriptive molecular epidemiology studies have shown that Mycobacterium tuberculosis whole genome sequencing can identify outbreaks and disease transmission events with higher resolution than conventional epidemiological investigations. Those studies have strengthened our understanding of genomic polymorphisms correlating with person-to-person transmission and helped resolve putative transmission clusters. To date, systematic genomic surveillance programs implemented for M. tuberculosis were only implemented in low-incidence settings. The purpose of this study is to determine whether there is an impact of routine M. tuberculosis whole genome sequencing on tuberculosis case detection in a high-incidence setting. A cluster randomized controlled trial will be performed. Forty-eight rural village groups (or Fokontany) in the Vohibato district of Madagascar will be randomized to one of three interventions arms. Arm 1 (standard of care) involves healthcare facility-based passive case detection with smear microscopy testing. Arm 2 (best practice) consists of active case finding and Xpert MTB/RIF Ultra PCR testing followed by household contact investigations. Arm 3 (novel intervention) includes the same interventions as arm 2, with addition of sputum culture and M. tuberculosis whole genome sequencing for all newly diagnosed cases. In arm 3, molecular suggested putative outbreaks are investigated, and additional TB suspects are appropriately tested. The intervention observational period will be 2 years. The primary outcome will be the number of detected cases/100,000/year in each arm after 1 year of intervention. This study is designed to determine whether there is an impact of prospective whole genome sequencing-based molecular typing on tuberculosis case detection in high-incidence settings. Investigating potential outbreaks and focusing active case finding in spatiotemporal settings where disease transmission is suggested by genomic typing is hypothesized to improve case detection in rural communities. ClinicalTrials.gov NCT05406453 . Retrospectively registered on June 6, 2022.
Sections du résumé
BACKGROUND
BACKGROUND
Retrospective and descriptive molecular epidemiology studies have shown that Mycobacterium tuberculosis whole genome sequencing can identify outbreaks and disease transmission events with higher resolution than conventional epidemiological investigations. Those studies have strengthened our understanding of genomic polymorphisms correlating with person-to-person transmission and helped resolve putative transmission clusters. To date, systematic genomic surveillance programs implemented for M. tuberculosis were only implemented in low-incidence settings. The purpose of this study is to determine whether there is an impact of routine M. tuberculosis whole genome sequencing on tuberculosis case detection in a high-incidence setting.
METHODS
METHODS
A cluster randomized controlled trial will be performed. Forty-eight rural village groups (or Fokontany) in the Vohibato district of Madagascar will be randomized to one of three interventions arms. Arm 1 (standard of care) involves healthcare facility-based passive case detection with smear microscopy testing. Arm 2 (best practice) consists of active case finding and Xpert MTB/RIF Ultra PCR testing followed by household contact investigations. Arm 3 (novel intervention) includes the same interventions as arm 2, with addition of sputum culture and M. tuberculosis whole genome sequencing for all newly diagnosed cases. In arm 3, molecular suggested putative outbreaks are investigated, and additional TB suspects are appropriately tested. The intervention observational period will be 2 years. The primary outcome will be the number of detected cases/100,000/year in each arm after 1 year of intervention.
DISCUSSION
CONCLUSIONS
This study is designed to determine whether there is an impact of prospective whole genome sequencing-based molecular typing on tuberculosis case detection in high-incidence settings. Investigating potential outbreaks and focusing active case finding in spatiotemporal settings where disease transmission is suggested by genomic typing is hypothesized to improve case detection in rural communities.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05406453 . Retrospectively registered on June 6, 2022.
Identifiants
pubmed: 39456079
doi: 10.1186/s13063-024-08537-4
pii: 10.1186/s13063-024-08537-4
doi:
Banques de données
ClinicalTrials.gov
['NCT05406453']
Types de publication
Journal Article
Clinical Trial Protocol
Langues
eng
Sous-ensembles de citation
IM
Pagination
717Informations de copyright
© 2024. The Author(s).
Références
Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: the Lancet Commission on tuberculosis. Lancet. 2019;393(10178):1331–84.
doi: 10.1016/S0140-6736(19)30024-8
pubmed: 30904263
WHO. The end TB strategy. Geneva: World Health Organization; 2015.
Allix-Beguec C, Arandjelovic I, Bi L, Beckert P, CRyPTIC., Project G, et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379(15):1403–15.
doi: 10.1056/NEJMoa1800474
pubmed: 30280646
Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, et al. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infect Dis. 2018;18(4):431–40.
doi: 10.1016/S1473-3099(18)30004-5
pubmed: 29326013
pmcid: 5864516
Tagliani E, Cirillo DM, Kodmon C, van der Werf MJ, Consortium EU. EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU. Lancet Infect Dis. 2018;18(4):377.
doi: 10.1016/S1473-3099(18)30132-4
Starks AM, Aviles E, Cirillo DM, Denkinger CM, Dolinger DL, Emerson C, et al. Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform. Clin Infect Dis. 2015;61Suppl 3:S141–6.
doi: 10.1093/cid/civ610
pubmed: 26409275
WHO. The use of next-generation sequencing technologies for the detection of mutations associated with drug-resistance in Mycobacterium tuberculosis complex: technical guide. World Health Organization - Foundation for Innovative and New Diagnostics. 2018.
WHO. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012.
Merker M, Kohl TA, Niemann S, Supply P. The evolution of strain typing in the Mycobacterium tuberculosis complex. Adv Exp Med Biol. 2017;1019:43–78.
doi: 10.1007/978-3-319-64371-7_3
pubmed: 29116629
Bryant JM, Schurch AC, van Deutekom H, Harris SR, de Beer JL, de Jager V, et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis. 2013;13:110.
doi: 10.1186/1471-2334-13-110
pubmed: 23446317
pmcid: 3599118
Pando C, Hazel A, Tsang LY, Razafindrina K, Andriamiadanarivo A, Rabetombosoa RM, et al. A social network analysis model approach to understand tuberculosis transmission in remote rural Madagascar. BMC Public Health. 2023;23(1):1511.
doi: 10.1186/s12889-023-16425-w
pubmed: 37558982
pmcid: 10410943
WHO. Global tuberculosis report 2023. 2024.
Knoblauch AM, Grandjean Lapierre S, Randriamanana D, Raherison MS, Rakotoson A, Raholijaona BS, et al. Multidrug-resistant tuberculosis surveillance and cascade of care in Madagascar: a five-year (2012–2017) retrospective study. BMC Med. 2020;18(1):173.
doi: 10.1186/s12916-020-01626-6
pubmed: 32600414
pmcid: 7325144
Sadananda G, Knoblauch AM, Andriamiadanarivo A, Razafimdriana K, Ambinintsoa I, Rabetombosoa RM, et al. Latent tuberculosis infection prevalence in rural Madagascar. Trop R Soc Trop Med Hyg. 2020.
Hall MB, Rabodoarivelo MS, Koch A, Dippenaar A, George S, Grobbelaar M, et al. Evaluation of nanopore sequencing for Mycobacterium tuberculosis drug susceptibility testing and outbreak investigation: a genomic analysis. Lancet Microbe. 2022.
Altman DG, Bland JM. Treatment allocation by minimisation. BMJ. 2005;330(7495):843.
doi: 10.1136/bmj.330.7495.843
pubmed: 15817555
pmcid: 556084
INSTAT. Troisième recensement général de la population et de l’habitation. 2019.
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;2014(1):CD009593.
pubmed: 24448973
pmcid: 4470349
Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570–81.
doi: 10.1016/S1473-3099(06)70578-3
pubmed: 16931408
Rakotosamimanana N, Lapierre SG, Raharimanga V, Raherison MS, Knoblauch AM, Raherinandrasana AH, et al. Performance and impact of GeneXpert MTB/RIF(R) and Loopamp MTBC Detection Kit(R) assays on tuberculosis case detection in Madagascar. BMC Infect Dis. 2019;19(1):542.
doi: 10.1186/s12879-019-4198-6
pubmed: 31221109
pmcid: 6585144
Rakotoarivelo R, Ambrosioni J, Rasolofo V, Raberahona M, Rakotosamimanana N, Andrianasolo R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar. Int J Infect Dis. 2018;69:20–5.
doi: 10.1016/j.ijid.2018.01.017
pubmed: 29408360
Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis. 2013;13(2):137–46.
doi: 10.1016/S1473-3099(12)70277-3
pubmed: 23158499
pmcid: 3556524
Hemming K, Girling AJ, Sitch AJ, Marsh J, Lilford RJ. Sample size calculations for cluster randomised controlled trials with a fixed number of clusters. BMC Med Res Methodol. 2011;11:102.
doi: 10.1186/1471-2288-11-102
pubmed: 21718530
pmcid: 3149598
Datiko DG, Lindtjorn B. Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS ONE. 2009;4(5):e5443.
doi: 10.1371/journal.pone.0005443
pubmed: 19424460
pmcid: 2678194
Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K, et al. Allocation techniques for balance at baseline in cluster randomized trials: a methodological review. Trials. 2012;13:120.
doi: 10.1186/1745-6215-13-120
pubmed: 22853820
pmcid: 3503622
Coart E, Bamps P, Quinaux E, Sturbois G, Saad ED, Burzykowski T, et al. Minimization in randomized clinical trials. Stat Med. 2023;42(28):5285–311.
doi: 10.1002/sim.9916
pubmed: 37867447
Donner A, Klar N. Methods for comparing event rates in intervention studies when the unit of allocation is a cluster. Am J Epidemiol. 1994;140(3):279–89 discussion 300–1.
doi: 10.1093/oxfordjournals.aje.a117247
pubmed: 8030631
Bank W. The World Bank data - IBRD IDA - Madagascar 2020 [Available from: https://data.worldbank.org/country/madagascar .
Worldometer. Population of Madagascar (2020 and historical) 2020 [Available from: https://www.worldometers.info/world-population/madagascar-population/ .
Rasolofo Razanamparany V, Menard D, Auregan G, Gicquel B, Chanteau S. Extrapulmonary and pulmonary tuberculosis in Antananarivo (Madagascar): high clustering rate in female patients. J Clin Microbiol. 2002;40(11):3964–9.
doi: 10.1128/JCM.40.11.3964-3969.2002
pubmed: 12409359
pmcid: 139634
Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis. 1998;2(2):96–104.
pubmed: 9562118